Ramasamy, K., Royle, K., Cicero, R., Tute, R. D., Jenner, M., Bygrave, C., Popat, R., Mehta, D., Chiecchio, L., Balik, B., Kazeroun, M., Pratt, G., Olivier, C., Barnard, L., Jackson, S., Kennaway, C., Cook, G., Chant, A., Meads, D., Dawkins, B., Chapman, M., Jackson, G., Chantry, A., Kaiser, M., Sive, J., Gooding, S., Boyle, E., Parrish, C., Smith, D., Chan, Y. L. T., Owen, R., Cairns, D., Yong, K. (2025). Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA)  RADAR trial in newly diagnosed transplant eligible patients. Blood. https://doi.org/10.1182/blood-2025-98